{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:58:21Z","timestamp":1780063101714,"version":"3.54.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"Importance<\/jats:title>Studies have linked bullous pemphigoid (BP) with venous thromboembolism (VTE) across several data sources finding 6-fold to 15-fold increased incidence rates.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the incidence of VTE in patients with BP compared with similar controls.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used insurance claims data from a nationwide US health care database from January 1, 2004, through January 1, 2020. Patients with dermatologist-recorded BP were identified (\u22652 diagnoses of BP [International Classification of Diseases, Ninth Revision (ICD-9)<\/jats:italic> 694.5 and ICD-10 <\/jats:italic>L12.0] recorded by dermatologists within 1 year). Risk-set sampling identified comparator patients without BP and free of other chronic inflammatory skin diseases. Patients were followed-up until the first of the following events occurred: VTE, death, disenrollment, or end of data stream.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Patients with BP compared with those without BP and free of other chronic inflammatory skin diseases (CISD).<\/jats:p><\/jats:sec>Main outcome<\/jats:title>Venous thromboembolism events were identified and incidence rates were computed before and after propensity-score (PS) matching to account for VTE risk factors. Hazard ratios (HRs) compared the incidence of VTE in BP vs non-CISD.<\/jats:p><\/jats:sec>Results<\/jats:title>Overall, 2654 patients with BP and 26\u202f814 comparator patients without BP or another CISD were identified. The mean (SD) age in the BP group was 73.0 (12.6) years and 55.0 (18.9) years in the non-CSID group. With a median follow-up time was 2 years, the unadjusted incidence rate (per 1000 person-years) of outpatient or inpatient VTE was 8.5 in the BP group compared with 1.8 in patients without a CISD. Adjusted rates were 6.7 in the BP group compared with 3.0 in the non-CISD group. Age-specific adjusted incidence rates (per 1000 person-years) in patients aged 50 to 74 years was 6.0 (vs 2.9 in the non-CISD group) and in those aged 75 years or older was 7.1 (vs 4.53 in the non-CISD group). After 1:1 propensity-score matching including 60 VTE risk factors and severity markers, BP was associated with a 2-fold increased risk of VTE (2.24 [1.26-3.98]) vs those in the non-CISD group. When restricting to patients aged 50 years or older, the adjusted relative risk of VTE was 1.82 (1.05-3.16) for the BP vs non-CISD groups.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In this nationwide US cohort study, BP was associated with a 2-fold increased incidence of VTE after controlling for VTE risk factors in a dermatology patient population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.1461","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T15:08:03Z","timestamp":1686150483000},"page":"750","source":"Crossref","is-referenced-by-count":11,"title":["Venous Thromboembolism in Patients With Bullous Pemphigoid"],"prefix":"10.1001","volume":"159","author":[{"given":"Maria C.","family":"Schneeweiss","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"dbr230006r1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","article-title":"Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases.","volume":"157","author":"Schneeweiss","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"dbr230006r2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jamadermatol.2021.3828","article-title":"Venous thromboembolism in chronic inflammatory skin diseases-the need to consider bullous pemphigoid-reply.","volume":"158","author":"Schneeweiss","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dbr230006r3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1160\/TH15-04-0309","article-title":"Increased risk of venous thromboembolism in patients with bullous pemphigoid: the INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.","volume":"115","author":"Cugno","year":"2016","journal-title":"Thromb Haemost"},{"issue":"4","key":"dbr230006r4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study.","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"dbr230006r5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamafacial.2018.0331","article-title":"Risk of venous thromboembolism in patients with keratinocyte carcinoma.","volume":"20","author":"Rudy","year":"2018","journal-title":"JAMA Facial Plast Surg"},{"issue":"2","key":"dbr230006r6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","article-title":"Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism.","volume":"180","author":"Walker","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"dbr230006r7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.thromres.2015.01.012","article-title":"Improving accuracy of international classification of diseases codes for venous thromboembolism in administrative data.","volume":"135","author":"Sanfilippo","year":"2015","journal-title":"Thromb Res"},{"issue":"8","key":"dbr230006r8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009960","article-title":"Chart validation of inpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTE) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database.","volume":"97","author":"Ammann","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"dbr230006r9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.ede.0000147164.11879.b5","article-title":"Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction.","volume":"16","author":"Schneeweiss","year":"2005","journal-title":"Epidemiology"},{"issue":"1","key":"dbr230006r10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity scores in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"dbr230006r11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies.","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"dbr230006r12","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1038\/s41467-022-32310-3","article-title":"Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions.","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"dbr230006r13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.v99.3","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"dbr230006r15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/jde.v49.8","article-title":"Association between bullous pemphigoid and risk of venous thromboembolism: a nationwide population-based cohort study.","volume":"49","author":"Chen","year":"2022","journal-title":"J Dermatol"},{"key":"dbr230006r14","unstructured":"Aetion Evidence Platform (2020). Software for real-world data analysis. Aetion, Inc. http:\/\/aetion.com"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2805528\/jamadermatology_schneeweiss_2023_br_230006_1689096816.48026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T15:19:35Z","timestamp":1689779975000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2805528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.1461","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}